Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908 is a research paper published in Neuro-Oncology (2023). On theSindex it has a DataRank of 1.3. It has been cited 65 times, with 58 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.628
From this paper's citation signal
Citation Network Contribution
0.639
From 42 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 58 citers.
National Cancer Institute
Grant: P30 CA008748
The Brain Tumour Charity
Grant: 16/193
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre
National Institute for Health Research (NIHR)
National Institutes of Health
Department of Health
FWCI
11.01
Citation Percentile
1.0%
Influential Citations
2
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals